China Life Insurance (Overseas) Company Limited Issuer Summary

Report date: 2026-05-18
Issuer: China Life Insurance (Overseas) Company Limited / China Life Insurance (Overseas) Company Limited, Hong Kong Branch
Ticker focus: CHILOV
Sector: Hong Kong and Macau life insurance
Primary credit focus: issuer credit, insurer financial strength, expectation of parental support, insurance liabilities and investment assets, Hong Kong and Macau life insurance franchise, and security risk of USD subordinated capital bonds

1. Business Snapshot and Recent Developments

China Life Insurance (Overseas) Company Limited (“China Life Overseas”) is the sole wholly owned overseas subsidiary of China Life Insurance (Group) Company. It is an insurer focused on life insurance, pension and retirement-related business, investment, group insurance, and subsidiaries in Singapore and Indonesia, with Hong Kong and Macau as its core markets. In this report, CHILOV refers not to the listed company China Life Insurance Company Limited (2628.HK / 601628.SH), but to China Life Overseas and the US dollar subordinated capital bonds issued by its Hong Kong branch. Confusing these entities would lead to an incorrect reading of the financials, regulatory capital, bond ranking, and parental support.

The starting point for credit analysis is to view the company as “the overseas life insurance platform of a Chinese state-owned insurance group” and, at the same time, as “an insurer that underwrites long-term insurance contract liabilities in Hong Kong and Macau and holds a large pool of investment assets against them.” The scale of the parent and its importance as a state-owned financial group are credit supports, but they do not constitute an explicit PRC government guarantee of the obligations of China Life Overseas or its Hong Kong branch. In particular, CHILOV’s 2023 US dollar subordinated capital bonds are expressly subordinated to policyholders, unsubordinated creditors, and obligations that rank senior by law or contract. It is therefore necessary to distinguish between issuer credit strength and the security’s loss-absorption ranking.

According to the company’s official profile, China Life Overseas had company assets of HKD452.8bn and combined revenue of HKD68.9bn as of end-December 2025. The company assets figure is presented in the official profile as an unaudited financial value. It differs in scope and nature from the audited financials for 2020-2022 and should not be mechanically compared as part of the same financial time series. However, it indicates that the company continues to maintain a large insurance balance sheet within Hong Kong and Macau. The official profile shows a Moody’s insurer financial strength rating of A1 and S&P long-term local currency issuer credit and insurer financial strength ratings of A. On external assessment, the company is therefore treated as an upper investment-grade insurance credit.

By contrast, the detailed public audited financials identified for this review are mainly the 2020-2022 data included in the offering circular for the 2023 US dollar subordinated capital bonds. Consolidated gross premiums were HKD49.2bn in 2022, down from HKD68.9bn in 2020, and net investment income fell to HKD8.3bn. Net profit increased to HKD3.2bn, but comprehensive income was a loss of HKD4.2bn, and total equity declined to HKD23.1bn. This illustrates that the credit strength of a life insurer should not be assessed solely by premium scale. This is an issuer affected simultaneously by the valuation of investment assets, interest rates, credit spreads, insurance liabilities, product mix transition, and capital regulation.

As a supplementary indicator of the company’s recent market position, the Insurance Authority’s 2025 long-term insurance statistics for Hong Kong show that the entity named China Life in the IA statistics had annualised premiums of HKD12.5bn for direct individual new business in Hong Kong, equivalent to about 7.4% of the overall Hong Kong market total of HKD168.6bn. This report treats the China Life designation as a supplementary statistic related to China Life Overseas / its Hong Kong branch in the Hong Kong market, and not as a financial indicator for the listed entity or the parent group as a whole. Because this is Hong Kong market statistics rather than a consolidated financial statement for a single insurer, it cannot be substituted for company-wide revenue or profit. That said, the figure is a useful reference point for franchise assessment, as it indicates that the company still has meaningful scale in Hong Kong’s new business market, particularly in annualised premiums rather than single premiums.

In one sentence, the current profile of China Life Overseas can be summarised as follows: it is a Hong Kong and Macau life insurer belonging to one of China’s largest state-owned insurance groups, with A-range external ratings and a large insurance balance sheet, but with detailed audited financials for 2023-2025, RBC capital buffers, and individual bond spreads not yet verified; subordinated bondholders should explicitly factor in subordination to policyholders and senior creditors.

2. Industry Position and Franchise Strength

China Life Overseas’ franchise is built on its long operating history in Hong Kong and Macau, the China Life brand, capital, brand and distribution support from the parent group, and a distribution network combining bancassurance and broker channels. The official profile states that the company was established in 1933, has a history of more than 90 years in Hong Kong, and is one of the largest Chinese-funded insurers and institutional investors in Hong Kong. It should be viewed not as a newly established overseas subsidiary, but as a platform that a mainland Chinese insurance group has built over a long period in the Hong Kong and Macau insurance markets.

The company’s position in the Hong Kong market is the most important business factor supporting its credit profile. The 2023 offering circular states that the Hong Kong branch had been among the top five insurers by premium income since 2012 and ranked first by new business APE in 2019-2021. In the 2025 IA statistics as well, annualised premiums for direct individual new business were HKD12.5bn, equivalent to about 7.4% of the total market. This report has not verified the exact ranking, but the data indicate that the company has maintained a core scale within Hong Kong’s long-term insurance market.

Macau is also important. The 2023 offering circular states that the Macau branch had been among the top two insurers by premium income since 2012 and ranked first by premium income in 2014-2021. Hong Kong and Macau are linked to cross-border demand, RMB, US dollar and Hong Kong dollar assets, insurance demand from high-net-worth and middle-class customers, and mainland Chinese customers’ need for asset diversification. This broadens sales opportunities, while also exposing the franchise to policy, travel, sales compliance, customer protection, and interest-rate-cycle factors.

The company’s strength lies not merely in having a brand, but in how that brand supports the stability of insurance liabilities and access to capital markets. The China Life Group name can support confidence among policyholders, bancassurance partners, institutional investors, and regulators. A large policyholder base underpins premium cash flow and long-term investment assets. A-range ratings support access to bond markets. However, brand and ratings do not eliminate claims, surrender risk, or investment valuation losses, nor do they improve the legal recovery priority of subordinated bondholders.

Viewed through the 2025 Hong Kong IA statistics, China Life in the IA statistics accounted for about 1.2% of the overall market by number of direct individual new business policies and about 0.6% by single premiums, but about 7.4% by annualised premiums. This difference suggests that the relevant Hong Kong insurance business may have a larger presence in annualised premiums and may be less skewed towards single-premium products than the overall market. However, product mix, margins, guaranteed rates, acquisition costs, and surrender rates have not been verified. The annualised premium share should therefore not be directly translated into profit share or credit headroom.

The franchise conclusion is that China Life Overseas is a high-quality insurance issuer with a large brand and distribution base in Hong Kong and Macau, but further review of new business value, product guarantees, surrender rates, sales commissions, and capital consumption is required to assess the quality of growth. The evidence currently available is sufficient to regard the franchise as a credit support, but not sufficient on its own to fully explain the company’s capital headroom or subordinated bond risk.

3. Segment Assessment

China Life Overseas’ businesses can be considered across long-term life and annuity insurance, retirement-related business, group insurance, investment management, and its Singapore and Indonesia subsidiaries. However, the detailed product-level financials identified in this review are mainly from the offering circular up to 2022, and this report does not infer product-level margins or CSM from the 2025 official profile figures. The segment assessment is therefore limited to the credit implications of premium composition, geographic mix, distribution channels, and the direction of product transition.

In 2022, life and annuity premiums were HKD44.2bn, accounting for about 89.9% of total premium income. The retirement benefits business contributed HKD4.9bn, or about 9.9%, while group health insurance and investment-linked long-term insurance were small. The company’s credit strength is therefore heavily driven by the quality of long-term life and annuity liabilities and the investment assets backing them. As an insurer, earnings are determined not only by premiums at the time of sale, but also by future claims, surrenders, guaranteed rates, investment yields, reinsurance, and regulatory capital.

On product strategy, the offering circular describes a transition away from short-term savings products towards longer-term, lower-guarantee, higher-value products. The contribution of products with premium payment terms of more than five years to first-year premiums rose from 38.9% in 2020 to 48.1% in 2021 and 65.9% in 2022. The contribution of low-guarantee participating products to first-year premiums also rose from 4.6% to 26.2% and then 60.6%. This can be read positively as a shift focused on liability persistence, ALM, capital efficiency, and new business value rather than short-term premium scale. However, whether this product transition has actually improved earnings and capital can only be confirmed by reviewing detailed 2023-2025 financials, CSM, surrender rates, and acquisition costs.

By distribution channel, bancassurance accounted for 64.8% of first-year premiums in 2022, brokers for 24.6%, tied agents for 9.3%, and other channels for 1.3%. Bancassurance provides large sales volumes and customer access, but is affected by banks’ sales policies, commissions, customer protection regulation, and competition from interest-rate products. Broker channels are better positioned to access high-net-worth and cross-border demand, but sales quality, commissions, product explanation, and regulatory oversight are important. The tied-agent share is small, so the earnings structure differs from that of large Taiwanese life insurers with extensive agency networks.

Geographically, Hong Kong accounted for 80.4% of premium income in 2022, Macau for 18.4%, and Singapore and Indonesia for 1.2%. For first-year premiums, Hong Kong accounted for 85.2%, Macau for 13.3%, and Singapore and Indonesia for 1.6%. The Singapore and Indonesia subsidiaries therefore provide strategic breadth, but the centre of credit analysis remains Hong Kong and Macau. Interest rates, travel patterns, cross-border sales, customer demand, and supervisory policy in Hong Kong and Macau directly affect the company’s insurance sales and surrenders.

The segment conclusion is that China Life Overseas’ credit strength is supported by its long-term life insurance franchise in Hong Kong and Macau and by its ability to shift from short-term savings products towards longer-term, lower-guarantee, higher-value products. However, product transition is not only a sales-volume issue. Even if the share of lower-guarantee products rises, customer acquisition costs, surrenders, claims, investment yields, and regulatory capital also matter. Once detailed 2025 disclosures become available, product-level profitability and capital consumption should be reviewed.

4. Financial Profile and Analysis

China Life Overseas’ financial profile is characterised by a large insurance balance sheet, A-range ratings, and a high solvency ratio as of 2022, but the assessment is constrained by declining premiums, investment-income volatility, swings in comprehensive income, and limited detailed disclosure for 2023-2025. The audited financials reviewed in this report are the consolidated and Hong Kong branch data for 2020-2022 included in the 2023 offering circular. The 2025 official profile figures are used as scale indicators, but are clearly separated from the audited time series.

Consolidated gross premiums fell from HKD68.9bn in 2020 to HKD59.7bn in 2021 and HKD49.2bn in 2022. This may have reflected restraint in short-term savings products, product-mix transition, market conditions, and changes in distribution channels. A decline in premium income may appear credit-negative in isolation, but if it reflects a reduction in short-term, high-guarantee, low-value products, it may be accompanied by improved capital efficiency and liability quality. The issue should therefore not be assessed simply as top-line decline; new business value, guaranteed rates, CSM, surrenders, and capital consumption should be reviewed together.

Net investment income fell sharply to HKD8.3bn in 2022 from HKD18.5bn in 2020 and HKD21.3bn in 2021. This is important for a life insurer with a fixed-income-heavy investment portfolio. Investment income is a key source of support for insurance liabilities, and interest rates, credit spreads, valuation gains and losses, dividends, liquidity, and hedging costs all affect earnings and capital. Net profit increased to HKD3.2bn in 2022, but comprehensive income was a loss of HKD4.2bn. Accounting net profit alone does not sufficiently capture capital movements.

Total assets declined gradually from HKD477.8bn in 2020 to HKD469.8bn in 2021 and HKD463.1bn in 2022. The 2025 official profile’s company assets figure of HKD452.8bn is an unaudited profile value as of end-December 2025. It suggests that assets have not grown materially from end-2022, but detailed balance sheet, investment asset, insurance liability, capital, and RBC data have not been obtained. Total equity was HKD23.1bn in 2022, below HKD26.2bn in 2020 and HKD27.3bn in 2021. For an insurer, not only the equity thickness relative to total assets but also the regulatory capital ratio and the amount of investment risk are important.

The solvency ratio was 257% in 2020, 282% in 2021, and 244% in 2022. These are high levels, but they are solvency ratios as of the offering circular period and do not show capital headroom under the Hong Kong RBC framework as of end-2025. For investment in insurance company bonds, it is necessary to review the latest RBC ratio, tier composition, capital treatment of subordinated bonds, and sensitivity to interest rates and spreads. In particular, redemption or call of subordinated capital bonds may depend on regulatory approval and capital headroom.

The Hong Kong branch on a standalone basis is also important. The issuer of the 2023 US dollar subordinated capital bonds is China Life Insurance (Overseas) Company Limited, Hong Kong Branch. In 2022, the Hong Kong branch had total assets of HKD351.3bn, total liabilities of HKD334.5bn, and equity of HKD16.7bn. The Hong Kong branch accounts for most of the consolidated company, but the consolidated group also includes the Macau branch, retirement-related business, and subsidiaries. Consolidated and Hong Kong branch figures should therefore not be conflated. Claims under an individual bond depend on the Hong Kong branch issuance terms and the legal structure of the company as a whole.

The financial assessment is that the company has large insurance assets and A-range ratings, but the data available through 2022 are not sufficient to verify 2025 capital headroom. The 244% solvency ratio in 2022 is supportive, but it is not current RBC headroom. The 2025 official profile figures of HKD452.8bn in company assets and HKD68.9bn in combined revenue are scale indicators, and company assets are presented as an unaudited figure, but they do not substitute for profitability, comprehensive income, capital, liquidity, investment portfolio, or the quality of insurance liabilities. This report therefore places the credit view toward the high-quality end, while treating the lack of detailed financials as a clear constraint.

5. Structural Considerations for Bondholders

For CHILOV investors, the most important structural issue is that the 2023 US dollar bonds are subordinated capital bonds issued by an insurer. The issuer is China Life Insurance (Overseas) Company Limited, Hong Kong Branch, and the securities are USD2.0bn 5.35% dated subordinated capital bonds due 2033. The fact that the parent is a Chinese state-owned insurance group and that the issuer is an A-range insurer is a credit support, but these bonds are not senior unsecured debt.

Under “Status and Subordination” in the offering circular, the bonds are direct, unconditional, unsecured, and subordinated obligations of the issuer, ranking behind all current and future policyholders, unsubordinated creditors, and obligations that rank senior by law or contract. In a winding-up, subordinated bondholders receive payment only after these senior obligations have been paid in full. This is a standard but important feature of insurance company debt, and it materially changes investors’ loss ranking. Risk should therefore not be assessed solely by the issuer rating.

The bonds mature in 2033 and have a first call on 15 August 2028. The initial coupon is 5.35%, and the bonds reset after the call date. The NDRC registration is dated 14 June 2023, and the Hong Kong insurance regulator’s letter is dated 18 July 2023. Redemption may involve regulatory approval where required. The 2028 call therefore depends on spread levels, refinancing cost, regulatory capital treatment, capital headroom, and regulatory approval. Even if a call may be economically rational or expected by market convention, this report does not assert call certainty.

Holders’ remedies are also limited. The offering circular explains that remedies for non-payment and related events differ from those of ordinary senior bonds and are mainly linked to winding-up proceedings. In subordinated capital bonds, as long as the issuer remains a going concern, payment deferral or regulatory-capital constraints may be reflected in market prices. Even where the issuer’s insurer financial strength is strong, the price of a subordinated security can react sharply to non-call risk, regulatory approval, ranking of interest and principal payments, and liquidation recovery.

Parental support should be assessed in two stages. China Life Overseas is the sole wholly owned overseas subsidiary of China Life Group and has high importance in terms of brand, capital, distribution, and strategy. The scale of the parent, its position as a state-owned financial group, and the issuer’s function as an overseas platform increase support expectations under stress. However, the offering circular also includes a risk that PRC government ownership and control do not guarantee the financial condition of the issuer or the parent. This report therefore treats parental and government support as credit-enhancing considerations, but not as an explicit guarantee or identical credit.

The structural conclusion is that CHILOV is close to a high-quality insurance company as an issuer, but the individual US dollar bonds carry clear additional risk as insurance company subordinated debt. They should not be treated simply as A-range insurer debt without incorporating policyholder protection, regulatory capital, redemption approval, the absence of guaranteed parental support, and liquidation ranking.

6. Capital Structure, Liquidity and Funding

Capital and liquidity analysis for China Life Overseas should consider asset liquidity, insurance liabilities, surrenders, investment asset quality, regulatory capital, and subordinated capital bonds together. This is not an issuer that can be analysed like a non-financial corporate using only EBITDA and financial debt. It underwrites long-term insurance contracts, invests primarily in fixed-income assets against those liabilities, and must meet claims, maturities, surrenders, and regulatory capital requirements.

At end-2022, consolidated investment assets were HKD419.9bn, representing most of total assets of HKD463.1bn. The investment portfolio consisted of 10.2% cash and bank deposits, 75.3% fixed-income investments, 2.3% equity investments, and 12.2% funds and others. A fixed-income-heavy composition is natural for assets backing insurance liabilities, and the low equity share reduces direct equity-market risk. However, even fixed-income assets are exposed to interest-rate increases, credit-spread widening, downgrades, duration mismatch, liquidity deterioration, and foreign-currency / Hong Kong dollar interest-rate differences, all of which affect capital and liquidity.

On fixed-income asset quality, the offering circular states that investment-grade fixed-income assets accounted for 88.9% in 2020, 87.7% in 2021, and 89.4% in 2022. This supports the view that the insurer maintained a high-quality investment portfolio. However, the investment-grade ratio does not show the current 2025 portfolio, and even within investment grade, A/BBB mix, issuer concentration, region, sector, maturity, mark-to-market valuation, and liquidity differ. The detailed portfolio as of 2025 has not been verified.

On capital, the 244% solvency ratio in 2022 is supportive, but the 2025 RBC ratio, tier composition, capital recognition of subordinated bonds, and stress sensitivity have not been obtained. At the time of the offering circular, the Hong Kong insurance regime was described as transitioning to the RBC framework. Current capital headroom should be assessed using the latest regulatory capital, required capital, and quality of capital, rather than the old solvency ratio. The ability to redeem subordinated capital bonds and the decision to call them may also be affected by this capital headroom.

For liquidity, confirmed sources of funding include premiums, investment income, cash and deposits, fixed-income assets, and market funding. Parent group support should be treated separately as a support expectation under stress, not as a confirmed committed line or guarantee. The fact that 10.2% of the 2022 investment portfolio was in cash and bank deposits supports immediate liquidity. However, in a stress scenario involving claims, maturities, surrenders, hedge collateral, and investment valuation losses at the same time, the key question is whether fixed-income assets can be converted into cash without losses. If cross-border demand in Macau and Hong Kong weakens, new business cash flow may decline at the same time.

Funding access is supported by official ratings and the parent brand. The company’s ability to issue USD2.0bn of subordinated capital bonds in 2023 demonstrates access to the international bond market. However, subordinated capital bonds are highly sensitive to refinancing costs. At the first call in 2028, if market spreads are wide, capital headroom is weak, regulatory approval is difficult, or refinancing is expensive, non-call risk may be reflected in the price.

The capital and liquidity conclusion is that China Life Overseas has large investment assets and A-range ratings and showed adequate solvency as of 2022, but the absence of the latest RBC and detailed investment portfolio is a major constraint. For subordinated bond investors, ongoing monitoring should focus not only on issuer liquidity, but also on regulatory capital, call decision, effectiveness of parental support expectations, and continued capital-market access.

7. Rating Agency View

China Life Overseas’ official profile shows a Moody’s insurer financial strength rating of A1 and S&P long-term local currency issuer credit and insurer financial strength ratings of A. The dates are 29 April 2026 for Moody’s and 8 February 2026 for S&P. These ratings indicate that the company is assessed by international investors as a strong A-range insurance issuer.

However, rating scales and rated obligations should be distinguished. Insurer financial strength ratings primarily assess the ability to pay policyholder obligations. Issuer credit ratings indicate the general credit strength of the issuer. Ratings on subordinated capital bonds may be notched down from issuer credit to reflect subordination, capital-like features, regulatory approval, payment restrictions, and liquidation recovery. In the 2023 offering circular, the bonds’ S&P expected rating was A-, one notch below the company’s S&P A. This indicates that CHILOV bonds should not be treated as identical to issuer risk.

This report has not obtained the latest detailed Moody’s and S&P rating reports, outlooks, upgrade and downgrade triggers, or the detailed treatment of group support. The extent to which rating agencies incorporate parental support, importance within a state-owned group, Hong Kong and Macau market position, investment assets, RBC, and subordinated bond notching remains a pending item for the next review. Ratings are inputs supporting this report’s credit view; they are not a substitute for analysis.

The central rating-based interpretation is that China Life Overseas has A-range insurer financial strength, while subordinated bonds naturally carry additional risk. A-range ratings support the issuer’s strength, relationship with the parent, franchise, capital, and liquidity, but do not guarantee the 2028 call, liquidation recovery, or regulatory approval. Even if ratings are maintained, spreads, call expectations, and subordinated bond prices will be affected by the individual terms and the market environment.

8. Credit Positioning

China Life Overseas is most naturally positioned as an A-range insurer under a Chinese state-owned insurance group, with a large franchise in the Hong Kong and Macau life insurance markets. Compared with a standalone mid-sized Hong Kong insurer, it has advantages in parent brand, support expectations, distribution and institutional-investor scale, and A-range ratings. On the other hand, unlike a broad listed insurance group such as AIA, its detailed public financials are limited, and its credit profile places a large weight on Hong Kong and Macau concentration and expectations of parental support.

Within the Chinese insurance sector, the company is the overseas platform of its parent, China Life Group, and is a separate credit from the listed mainland life insurance entity. The scale, listed disclosures, solvency, and asset portfolio of the mainland Chinese entity cannot be directly applied to China Life Overseas. Conversely, on a standalone basis, China Life Overseas’ credit profile centres on its market position in Hong Kong and Macau and support expectations from the parent. The appropriate comparables are therefore not necessarily large mainland Chinese insurers themselves, but major life insurers operating in Hong Kong and Macau, financial subsidiaries with parental support, and insurance company subordinated bonds.

By security class, issuer credit and the USD subordinated capital bonds should be separated. Issuer credit is supported by A-range ratings, unaudited company assets of HKD452.8bn as of end-December 2025 in the official profile, the Hong Kong and Macau franchise, and strategic importance to the parent. By contrast, the 2023 subordinated capital bonds are subordinated to policyholders and unsubordinated creditors, and involve regulatory approval and limited remedies. Therefore, even under the same “CHILOV” ticker, conclusions will differ depending on whether the analysis concerns the issuer’s credit strength or the spread, call, and recovery ranking of the USD subordinated bonds.

On relative value, this report has not reviewed market price, yield, spread, OAS, CDS, or comparison with same-maturity insurance subordinated bonds. It therefore does not make a buy, hold, or sell investment recommendation. On fundamentals, CHILOV is close to a high-quality A-range insurance credit, but whether the risk premium is adequate for the subordinated bonds can be judged only after reviewing individual bond prices, call assumptions, liquidity, and peer comparisons.

The credit positioning conclusion is to view China Life Overseas as “a strong Hong Kong and Macau life insurer with parental support expectations,” while applying “a stricter assessment to subordinated capital bonds than to senior issuer credit.” A strong parent and A-range ratings are supports, but limited detailed financial disclosure, unverified latest RBC, subordinated ranking, and call uncertainty remain constraints on investment analysis.

9. Key Credit Strengths and Constraints

The first credit strength of China Life Overseas is its strategic importance as the sole wholly owned overseas subsidiary of China Life Group. The parent is one of China’s largest state-owned insurance groups, and the official profile shows 2025 parent consolidated revenue of RMB1.28tn, consolidated total assets of RMB8.56tn, third-party assets under management of RMB3.0tn, and a Fortune Global 500 rank of 45. These do not guarantee the issuer’s obligations, but they support brand, expectations of capital support, customer confidence, and market access.

The second strength is the Hong Kong and Macau franchise. The 2023 offering circular states that the Hong Kong branch ranked among the top five by premium income and the Macau branch among the top two. The 2025 IA statistics also show that China Life in the IA statistics had about a 7.4% market share in annualised premiums for Hong Kong direct individual new business. Here as well, this is treated as a supplementary statistic for the relevant Hong Kong insurance business, not for the listed entity or the parent group as a whole. Meaningful presence in the Hong Kong and Macau life insurance markets supports premium cash flow, investment asset scale, and relationships with regulators and distribution channels.

The third strength is that most investment assets are fixed-income assets, and about 89.4% of fixed-income assets were investment grade as of 2022. This indicates the quality of assets backing insurance liabilities, while direct sensitivity to equity market risk appears limited. The 244% solvency ratio in 2022 is also a support, indicating capital headroom at that time.

The first constraint is limited detailed financial disclosure. Company assets and combined revenue in the 2025 official profile have been verified, but audited profit and loss, comprehensive income, investment assets, insurance liabilities, capital, RBC, liquidity, and product-level profitability for 2023-2025 have not been obtained. A-range ratings are supportive, but from an analyst’s perspective, the inability to verify the latest capital headroom and investment risk should be treated as a clear information constraint.

The second constraint is market and ALM risk as a life insurer. In 2022, net investment income declined sharply and comprehensive income was negative. Fixed-income-heavy investment assets support insurance liabilities, but they are sensitive to interest rates, credit spreads, valuation losses, liquidity, foreign exchange, and duration mismatch. The transition towards longer-term, lower-guarantee products is positive, but product-level guaranteed rates, surrender rates, acquisition costs, and capital consumption have not been verified.

The third constraint is the subordinated bond structure. The USD2.0bn 2023 subordinated capital bonds are subordinated to policyholders and unsubordinated creditors even if the issuer is strong. Regulatory approval, non-call risk, limited remedies, and liquidation recovery affect pricing. CHILOV subordinated bonds should therefore not be treated as having the same risk as senior financial bonds in the same rating range.

10. Downside Scenarios and Monitoring Triggers

The most realistic downside is simultaneous stress on investment assets and insurance liabilities. For a fixed-income-heavy life insurer, higher interest rates create valuation losses on existing bonds, credit-spread widening erodes capital, and liquidity declines. Even when interest rates fall, if the guaranteed rates on previously sold products are high, lower reinvestment yields can pressure investment spreads. The decline in net investment income and comprehensive loss in 2022 show that this type of risk can actually appear in the financials.

The second downside is a scenario in which new business demand in Hong Kong and Macau weakens and the quality of product transition deteriorates. Life insurance demand in Hong Kong and Macau is affected by interest rates, cross-border customers, high-net-worth demand, distribution channels, regulation, and customer protection. If the transition from short-term savings products to longer-term, lower-guarantee, higher-value products stalls and the company reverts to high-guarantee, high-commission, low-margin products, premiums may grow but capital burden would increase. Conversely, even if sales volume declines, credit implications are not necessarily negative if the mix shifts towards lower-guarantee, more capital-efficient products.

The third downside is a decline in parental support expectations. The status as a wholly owned subsidiary of China Life Group is supportive, but it is not an explicit guarantee by the parent or the PRC government. If the parent’s credit quality, capital policy, willingness to support overseas subsidiaries, regulatory constraints, or cross-border capital mobility changes, CHILOV’s credit assessment could change. For subordinated bonds in particular, even if the parent provides going-concern support, it does not necessarily support calls or market prices.

The fourth downside is the issue of regulatory capital and the subordinated bond call. The 2022 solvency ratio was high, but 2025 RBC headroom has not been verified. If RBC declines and the capital recognition of the subordinated capital bonds becomes necessary, non-call risk in 2028 could increase. Even if the issuer does not default, a decline in call expectations can materially affect subordinated bond prices. Because regulatory approval is required to the extent applicable, the call decision is not determined by the issuer’s intention alone.

Monitoring items are as follows.

The downside conclusion is that the risk of rapid credit deterioration at China Life Overseas does not appear high at present, given the A-range ratings, parental support expectations, and Hong Kong and Macau franchise. However, subordinated bond prices can move faster than issuer credit. In particular, deterioration in latest RBC, investment losses, weaker parental support expectations, and non-call concerns are likely to appear in spreads before an issuer default.

11. Credit View and Monitoring Focus

China Life Overseas’ current issuer credit strength can be assessed as a high-quality Hong Kong and Macau life insurance credit consistent with A-range ratings. The direction is more stable than improving, because detailed audited financials for 2023-2025 and the latest RBC have not been verified. Based on parental support expectations, unaudited company assets of HKD452.8bn as of end-December 2025 in the official profile, the Hong Kong and Macau franchise, and the 244% solvency ratio as of 2022, the likelihood of a sharp near-term decline in issuer credit appears low at present. However, the market price, call expectations, and recovery ranking of the subordinated capital bonds could deteriorate faster than issuer credit.

The most important supports for credit strength are the strategic importance of China Life Overseas as the wholly owned overseas subsidiary of China Life Group and its insurance franchise in Hong Kong and Macau. The scale of the parent, the brand of a state-owned financial group, A-range ratings, and a long operating history in the Hong Kong and Macau markets support policyholder confidence and access to capital markets. The 2025 IA statistics showing the presence of China Life in annualised premiums for Hong Kong direct individual new business also provide supporting evidence for the business base of the relevant Hong Kong insurance operation.

At the same time, the key constraint on the credit view is thin information. The 2025 official profile shows total assets and combined revenue, but it does not provide investment assets, insurance liabilities, comprehensive income, RBC, product-level profit, surrender rates, ALM, liquidity, or the capital recognition of the subordinated bonds. In the audited 2020-2022 data, gross premiums declined, net investment income fell sharply in 2022, and comprehensive income turned negative. This indicates that market and ALM sensitivity should not be underestimated for this insurer.

By security class, issuer credit and USD subordinated capital bonds should be clearly separated. For senior issuer credit, A-range ratings, parental support expectations, and a large insurance balance sheet are strong supports. For the 2023 USD2.0bn subordinated capital bonds, however, investors need to factor in subordination to policyholders and unsubordinated creditors, regulatory approval, limited remedies, and uncertainty around the 2028 call. Even if the issuer remains sound, the risk to subordinated bondholders is higher than that of senior debt.

For monitoring closer to investment decision-making, the first priority is to obtain detailed 2025 or 2026 financials and RBC. Next, the current price, yield, spread, OAS, peer comparison with other insurance subordinated bonds, 2028 call assumptions, and liquidity for the 2023 bonds need to be reviewed. On fundamentals, CHILOV can be considered a high-quality insurance credit, but because current market levels have not been reviewed, this report does not make a buy, hold, or sell relative-value judgement.

The conclusion of this report is to view China Life Overseas as “a high-quality issuer supported by parental support expectations and its Hong Kong and Macau life insurance franchise,” while also stating that “for subordinated capital bonds, investors should incorporate information constraints, unverified latest RBC, policyholder priority, and uncertainty around the 2028 call.” In the next update, if the latest annual financials, RBC, detailed rating reports, and individual bond spreads can be obtained, the credit view can be more clearly assigned to either an improving bias or a stable-maintained view.

12. Short Summary & Conclusion

China Life Insurance (Overseas) Company Limited is the sole wholly owned overseas subsidiary of China Life Insurance (Group) Company and is a high-quality insurance credit supported by its Hong Kong and Macau life insurance franchise, A-range ratings, and unaudited company assets of HKD452.8bn as of end-December 2025 in the official profile. However, the 2023 USD2.0bn subordinated capital bonds mainly referenced under CHILOV are subordinated to policyholders and unsubordinated creditors and involve regulatory approval, uncertainty around the 2028 call, and limited remedies. The direction of issuer credit is more stable than improving, but detailed 2023-2025 financials, the latest RBC, detailed rating reports, and bond spreads have not been verified. These need to be reviewed for individual security analysis.

13. Sources

Primary Company and Offering Sources

• China Life Insurance (Overseas) Company Limited, company profile, accessed 2026-05-18.
  https://www.chinalife.com.hk/about-us/clo
• HKEXnews, China Life Insurance (Overseas) Company Limited, Hong Kong Branch, US$2,000,000,000 5.35% Dated Subordinated Capital Bonds due 2033, offering circular dated 2023-08-08 and published 2023-08-16, accessed 2026-05-18.
  https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0816/2023081600153.pdf

Regulatory and Market Statistics

• Insurance Authority, Provisional Statistics on Hong Kong Long Term Business: January to December 2025, updated 2026-04-21, accessed 2026-05-18.
  https://www.ia.org.hk/en/infocenter/statistics/files/4q25long.pdf

Rating Sources

• China Life Insurance (Overseas) Company Limited official company profile, rating section: Moody's A1 insurer financial strength rating as of 2026-04-29; S&P A long-term local currency issuer credit rating and insurer financial strength rating as of 2026-02-08.
• HKEX offering circular for the 2023 USD subordinated capital bonds: S&P A- expected bond rating; company Moody's A1 insurer financial strength rating and S&P A issuer credit / financial strength ratings at issuance.

Internal Source Files

• issuer_summary/issuers/china_life_insurance_overseas/data/china_life_overseas_2023_subordinated_bond_oc.pdf
• issuer_summary/issuers/china_life_insurance_overseas/data/china_life_overseas_2023_subordinated_bond_oc.txt
• issuer_summary/issuers/china_life_insurance_overseas/data/china_life_insurance_overseas_source_extract_20260518.json

Unverified / Pending

• Detailed audited financial statements, comprehensive income, investment asset breakdown, insurance liability breakdown, cash flow, and liquidity ladder for 2023-2025 have not been obtained.
• The latest Hong Kong RBC ratio as of end-2025 or later, tier composition, capital recognition of subordinated capital bonds, and regulatory-capital stress sensitivity have not been verified.
• The latest detailed Moody's and S&P rating reports, outlooks, upgrade and downgrade triggers, and detailed treatment of parental support and government support have not been obtained.
• The detailed trust deed for the 2023 USD subordinated capital bonds, the full debt list, unused liquidity, maturity profile, and internal liquidity ladder have not been verified.
• The current price, yield, spread, OAS, liquidity, peer comparison, and 2028 call assumptions for the 2023 USD subordinated capital bonds have not been verified. This report does not make a buy, hold, or sell judgement based on market levels.
• Product-level guaranteed rates, CSM, surrender rates, acquisition costs, claims and loss ratios, reinsurance, ALM duration gap, and the latest standalone financials for the Macau branch and the Singapore and Indonesia subsidiaries have not been verified.